New trial results examine whether there's a drug superior to sorafenib when it comes to treating kidney cancer.
An interim analysis of the CheckMate 920 phase IIIb/IV trial evaluated nivolumab plus ipilimumab in advanced renal cell carcinoma patients with brain metastases.
Findings from a planned subanalysis of IMmotion151 looked at combination atezolizumab and bevacizumab in patients with RCC and sarcomatoid histology.
The phase II IMmotion150 study evaluated disease- and treatment-related symptoms in RCC patients receiving atezolizumab alone or in combination with bevacizumab vs sunitinib.
In this randomized phase III trial, researchers compared cytoreductive nephrectomy vs sunitinib alone in patients with metastatic renal cell carcinoma.
The KEYNOTE-426 study evaluated pembrolizumab plus axitinib vs sunitinib in patients with metastatic RCC with intermediate/poor risk disease and those with sarcomatoid features.
The bar for the standard of care among patients with advanced renal cell carcinoma is set high as various promising combination therapies recently received FDA approval.
Analyzing somatic and germline mutations and MSI may reveal clinically actionable mutations in a proportion of patients with advanced RCC.
A recent study in The Lancet Oncology suggests that the benefits of one tyrosine kinase inhibitor may extend to other subtypes of RCC.
Research presented at ASCO GU 2019 compared PFS with avelumab and axitinib vs sunitinib in patients with advanced renal cell carcinoma.